CHADS2 score: clinical prediction rule for assessing the
risk of stroke in patients with non-rheumatic atrial fibrillation. The
result can be used to determine whether or not treatment is required with
anticoagulation therapy or antiplatelet therapy. A high CHADS2
score corresponds to a greater risk of stroke, while a low CHADS2
score corresponds to a lower risk of stroke. The CHADS2 score was
validated by a study of nonrheumatic atrial fibrillation patients aged 65 to 95
who were not prescribed the anticoagulant warfarin.
Gage BF, van Walraven C, Pearce L, et al. (2004). "Selecting patients with
atrial fibrillation for anticoagulation: stroke risk stratification in patients
taking aspirin". Circulation 110 (16): 2287–92.
Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001).
"Validation of clinical classification schemes for predicting stroke: results
from the National Registry of Atrial Fibrillation". JAMA 285 (22): 2864–70.
Go AS, Hylek EM, Chang Y, et al.
Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation: How Well
Do Randomized Trials Translate Into Clinical Practice? JAMA.